[AXGN] AxoGen, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.5 Change: -0.05 (-0.58%)
Ext. hours: Change: 0 (0%)

chart AXGN

Refresh chart

Strongest Trends Summary For AXGN

AXGN is in the long-term up 469% in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AxoGen, Inc. operates as a medical technology company. It focuses on advancing the science and commercialization of peripheral nerve repair solutions. It offers a range of surgical nerve repair solutions, including Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. The company?s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It procures and processes its tissue products in the United States, Canada, Italy, Austria, the United Kingdom, the Netherlands, Israel, and Switzerland. AxoGen, Inc. is headquartered

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.49% Sales Growth - Q/Q3.27% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-60.58% ROE2506.62% ROI
Current Ratio7.57 Quick Ratio6.6 Long Term Debt/Equity1.12 Debt Ratio-5.05
Gross Margin80.01% Operating Margin-50.21% Net Profit Margin-91.49% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities13.59 M Cash From Operating Activities-40 K Gross Profit3.97 M
Net Profit-2.51 M Operating Profit-2.54 M Total Assets28.14 M Total Current Assets26.02 M
Total Current Liabilities3.44 M Total Debt25.27 M Total Liabilities28.82 M Total Revenue4.95 M
Technical Data
High 52 week55.9 Low 52 week14.62 Last close14.62 Last change-11.98%
RSI34.8 Average true range1.7 Beta0.31 Volume57.96 K
Simple moving average 20 days-18.76% Simple moving average 50 days-44.83% Simple moving average 200 days-61.88%
Performance Data
Performance Week-5.86% Performance Month-48.88% Performance Quart-57.72% Performance Half-71.33%
Performance Year-47.32% Performance Year-to-date-28.44% Volatility daily8.98% Volatility weekly20.07%
Volatility monthly41.13% Volatility yearly142.48% Relative Volume176.98% Average Volume814.29 K
New High New Low

News

2019-10-03 13:40:00 | Scott+Scott Attorneys at Law LLP Investigating Axogen, Inc.'s Directors and Officers for Breach of Fiduciary Duties - AXGN

2019-09-20 10:38:00 | Why AxoGen, Inc.'s NASDAQ:AXGN CEO Pay Matters To You

2019-09-19 07:00:00 | Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

2019-09-11 20:00:00 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Mammoth Energy, Acer Therapeutics, Realogy Holdings, and AxoGen and Encourages Investors to Contact the Firm

2019-08-27 07:00:00 | Axogen to Participate in the 74th Annual American Society for Surgery of the Hand Meeting

2019-08-18 17:59:18 | Weekly CEO Buys Highlight

2019-08-14 21:02:29 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett, Molson Coors, AxoGen, and American Renal Associates and Encourages Investors to Contact the Firm

2019-08-14 13:55:00 | Shareholder Alert: Robbins Arroyo LLP Announces Complaint Filed Against AxoGen, Inc. AXGN

2019-08-12 10:15:02 | Axogen Inc AXGN CEO Karen L. Zaderej Bought $1 million of Shares

2019-08-07 05:04:11 | Edited Transcript of AXGN earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-06 20:24:22 | AxoGen Inc AXGN Q2 2019 Earnings Call Transcript

2019-08-06 18:55:10 | AxoGen AXGN Reports Q2 Loss, Misses Revenue Estimates

2019-08-06 14:11:53 | Does AxoGen NASDAQ:AXGN Have A Healthy Balance Sheet?

2019-07-30 10:38:02 | Earnings Preview: AxoGen AXGN Q2 Earnings Expected to Decline

2019-07-29 07:00:00 | Axogen, Inc. to Participate at Canaccord Genuity 39th Annual Growth Conference

2019-07-26 07:50:00 | AXGN Alert: Johnson Fistel, LLP Announces Investigation of AxoGen, Inc.; Long Term Investors Encouraged to Contact Firm

2019-07-26 07:00:00 | Axogen Announces Publication of the 100th Peer-Reviewed Clinical Paper Featuring its Product Portfolio for Peripheral Nerve Repair

2019-07-23 07:00:00 | Axogen, Inc. to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6, 2019

2019-07-22 18:44:15 | Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of AxoGen NASDAQ: AXGN and Encourages AxoGen Investors to Contact the Firm

2019-07-19 12:09:07 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of AxoGen, Inc. - AXGN

2019-06-18 14:40:02 | Have Insiders Been Selling AxoGen, Inc. NASDAQ:AXGN Shares This Year?

2019-06-14 16:38:29 | Here’s What Hedge Funds Think About AxoGen, Inc. AXGN

2019-05-23 07:00:00 | Axogen, Inc. to Participate at Upcoming Investor Conferences

2019-05-09 01:34:56 | Edited Transcript of AXGN earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-09 00:23:47 | AxoGen Inc AXGN Q1 2019 Earnings Call Transcript

2019-05-08 17:45:09 | AxoGen AXGN Reports Q1 Loss, Tops Revenue Estimates

2019-05-08 16:41:23 | AxoGen: 1Q Earnings Snapshot

2019-05-08 16:01:00 | Axogen, Inc. Reports 2019 First Quarter Financial Results

2019-05-04 21:39:09 | Here’s What Hedge Funds Think About AxoGen, Inc. AXGN

2019-05-02 07:00:00 | Axogen, Inc. Appoints New Members to Board of Directors

2019-05-01 10:32:02 | Analysts Estimate AxoGen AXGN to Report a Decline in Earnings: What to Look Out for

2019-04-22 07:01:00 | Axogen, Inc. Announces Completion of Planned Interim Analysis and One-Time Enrollment Expansion for RECON® Study

2019-04-22 07:00:00 | Axogen, Inc. to Report First Quarter 2019 Financial Results and Host Conference Call on May 8, 2019

2019-04-16 15:28:59 | Is There An Opportunity With AxoGen, Inc.'s NASDAQ:AXGN 48% Undervaluation?

2019-03-22 18:26:00 | Lifshitz & Miller LLP Announces Investigation of 22nd Century Group, Activision Blizzard, Inc., Astec Industries, Inc., Avon Products, Inc., Axogen, Inc., Everquote Inc. and Health Insurance Innovations, Inc.

2019-03-20 11:54:00 | Robbins Arroyo LLP: AxoGen, Inc. AXGN Misled Shareholders According to Class Action

2019-03-11 11:19:46 | CLASS ACTION UPDATE for AXGN, MKL, VALE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-11 10:44:00 | FINAL DEADLINE - AXGN AxoGen, Inc. - Bronstein, Gewirtz & Grossman, LLC

2019-03-10 22:50:00 | AXOGEN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against AxoGen, Inc. - AXGN

2019-03-10 18:00:00 | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AxoGen, Markel, Maxar, and Wirecard and Encourages Investors to Contact the Firm

2019-03-10 10:05:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AXGN, MAXR and ATVI

2019-03-08 22:50:00 | AXOGEN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against AxoGen, Inc. - AXGN

2019-03-08 21:30:22 | DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-03-08 18:07:00 | KESSLER TOPAZ MELTZER & CHECK, LLP:  Final Deadline Reminder for AXOGEN, INC. Investors – AXGN

2019-03-08 13:13:37 | What Should We Expect From AxoGen, Inc.’s NASDAQ:AXGN Earnings Over The Next Few Years?

2019-03-08 11:50:00 | AXGN MARCH 11 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AxoGen, Inc. - AXGN

2019-03-08 09:40:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DNKEY, AXGN and MAXR

2019-03-07 19:54:36 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AxoGen, Inc. - AXGN

2019-03-07 18:40:00 | SHAREHOLDER ALERT: AXGN MKL STMP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2019-03-07 18:18:00 | 4-Day Deadline Alert: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against AxoGen, Inc.